AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Vistagen shares surge 16.32% after-hours as Stifel reiterates Buy rating and $12 price target on positive PAL-2 trial data.
ByAinvest
Monday, Nov 17, 2025 4:19 pm ET1min read
Vistagen Therapeutics (NASDAQ:VTGN) surged 16.32% in after-hours trading following Stifel’s reiterated Buy rating and $12.00 price target, a 197% upside from its $4.04 share price. The research firm highlighted positive data from VistaGen’s fasedienol PAL-2 trial, despite the earlier PAL-1 trial failing to achieve statistical significance, which management attributed to pandemic-related challenges. Stifel noted VistaGen’s improved trial designs for upcoming PAL-3 and PAL-4 studies, expected in 2025-2026, and the company’s strong cash position revealed in its Q2 2025 earnings call. These developments reinforced confidence in VistaGen’s pipeline advancements for social anxiety disorder treatments, aligning with the analyst firm’s optimism about regulatory and clinical progress.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet